Tarsus Pharmaceuticals, Inc. Common Stock
TARSTarsus Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for eye diseases, particularly those with high unmet medical needs. The company emphasizes the development of targeted treatments for conditions such as Demodex blepharitis, aiming to improve patient outcomes through novel pharmaceutical solutions.
Company News
Tarsus Pharmaceuticals reported first quarter 2026 XDEMVY net product sales exceeding $145 million, representing an 85% year-over-year increase. The company reaffirmed its full-year 2026 guidance of $670-700 million in XDEMVY sales and announced participation in three upcoming investor conferences in May.
Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares worth approximately $839,000 between March 17-19, 2026. The sale was a non-discretionary, tax-withholding-driven transaction tied to RSU vesting rather than a reflection of insider sentiment. Despite the insider sale, the company continues to show str...
Tarsus Pharmaceuticals will host a live webcast on November 4, 2025, to report its third quarter 2025 financial results and provide a corporate update. The company has FDA-approved XDEMVY for Demodex blepharitis and is developing additional treatments for eye care and infectious disease prevention.
Capricorn Fund Managers Ltd acquired 484,500 shares of Phreesia, valued at $11.4 million, representing 3.8% of their reportable assets under management. The investment comes as Phreesia reaches a milestone of first quarterly net income and plans to expand payment solutions.
DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development.
